High Throughput Screening Identifies Novel Lead Compounds with Activity against Larval, Juvenile and Adult Schistosoma mansoni

PLoS Neglected Tropical Diseases

Volumn 10, Issue 4, 2016, Pages

  Mansour, Nuha R ^a   Paveley, Ross ^a   Gardner, J Mark F ^b   Bell, Andrew S ^b   Parkinson, Tanya ^b   Bickle, Quentin ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b Salvensis ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; PRAZIQUANTEL; ANTHELMINTIC AGENT;

ADULT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY ASSAY; EC50; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC50; IMAGE ANALYSIS; JUVENILE; LARVA; MOUSE; NONHUMAN; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; ANIMAL; BIOASSAY; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; ISOLATION AND PURIFICATION; PRECLINICAL STUDY; SURVIVAL ANALYSIS;

ANIMALS; ANTHELMINTICS; BIOLOGICAL ASSAY; CELL LINE; CELL SURVIVAL; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LARVA; SCHISTOSOMA MANSONI; SURVIVAL ANALYSIS;

EID: 84964868724     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0004659     Document Type: Article

References (25)

1. King C.H., Parasites and poverty: the case of schistosomiasis. Acta Trop, 2010. 113(2): p. 95–104. doi: 10.1016/j.actatropica.2009.11.01219962954
2. Fenwick A., et al., The Schistosomiasis Control Initiative (SCI): rationale, development and implementation from 2002–2008. Parasitology, 2009. 136(13): p. 1719–30. doi: 10.1017/S003118200999040019631008
3. Doenhoff M.J., Cioli D., Utzinger J., Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis, 2008. 21(6): p. 659–67. doi: 10.1097/QCO.0b013e328318978f18978535
4. Doenhoff M.J., et al., Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology, 2009. 136(13): p. 1825–35. doi: 10.1017/S003118200900049319281637
5. Cioli D., Pica-Mattoccia L., Praziquantel. Parasitol Res, 2003. 90Supp 1: p. S3–9. 12811543
6. Pica-Mattoccia L., Cioli D., Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. Int J Parasitol, 2004. 34(4): p. 527–33. 15013742
7. Sabah A.A., et al., Schistosoma mansoni: chemotherapy of infections of different ages. Exp Parasitol, 1986. 61(3): p. 294–303. 3086114
8. Ramirez B, B. Q., Yousif F, Fakorede FK, Mouries M-A, Nwaka S, Schistosomes: challenges in compound screening. Expert Opinion on Drug Discovery, 2007. 2: p. S53–361. doi: 10.1517/17460441.2.S1.S5323489033
9. Ferreira L.G., Oliva G., Andricopulo A.D., Target-based molecular modeling strategies for schistosomiasis drug discovery. Future Medicinal Chemistry, 2015. 7(6): p. 753–764. doi: 10.4155/fmc.15.2125996068
10. Oliveira G., Pierce R.J., How has the genomics era impacted schistosomiasis drug discovery?Future Medicinal Chemistry, 2015. 7(6): p. 685–687. doi: 10.4155/fmc.15.3025996060
11. Paveley R.A., et al., Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases. PLoS Negl Trop Dis, 2012. 6(7): p. e1762. doi: 10.1371/journal.pntd.000176222860151
12. Mansour N.R., Bickle Q.D., Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening. PLoS Negl Trop Dis, 2010. 4(8): p. e795. doi: 10.1371/journal.pntd.000079520706580
13. Abdulla M.H., et al., Drug discovery for schistosomiasis: hit and lead compounds identified in a library of known drugs by medium-throughput phenotypic screening. PLoS Negl Trop Dis, 2009. 3(7): p. e478. doi: 10.1371/journal.pntd.000047819597541
14. Peak E., Chalmers I.W., Hoffmann K.F., Development and validation of a quantitative, high-throughput, fluorescent-based bioassay to detect schistosoma viability. PLoS Negl Trop Dis, 2010. 4(7): p. e759. doi: 10.1371/journal.pntd.000075920668553
15. De Rycker M., et al., Comparison of a High-Throughput High-Content Intracellular Leishmania donovani Assay with an Axenic Amastigote Assay. Antimicrob Agents Chemother, 2013. 57(7): p. 2913–2922. doi: 10.1128/AAC.02398-1223571538
16. Gamo F.J., et al., Thousands of chemical starting points for antimalarial lead identification. Nature, 2010. 465(7296): p. 305–10. doi: 10.1038/nature0910720485427
17. Lipinski C.A., et al., Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advances in Drug Delivery Reviews, 2001. 46(1–3): p. 3–26.
18. Avery V., et al., Screening and hit evaluation of a chemical library against blood-stage Plasmodium falciparum. Malaria Journal, 2014. 13(1): p. 190.
19. Simeonov A., et al., Quantitative High-Throughput Screen Identifies Inhibitors of the Schistosoma mansoni Redox Cascade. PLoS Negl Trop Dis, 2008. 2(1): p. e127. doi: 10.1371/journal.pntd.000012718235848
20. Lea W.A., et al., A 1,536-Well-Based Kinetic HTS Assay for Inhibitors of Schistosoma mansoni Thioredoxin Glutathione Reductase. ASSAY and Drug Development Technologies, 2008. 6(4): p. 551–555. doi: 10.1089/adt.2008.14918665782
21. Keseru G.M., Makara G.M., The influence of lead discovery strategies on the properties of drug candidates. Nature Reviews: Drug Discovery, 2009. 8(3): p. 203–212. doi: 10.1038/nrd279619247303
22. Andrews P., et al., Praziquantel. Medicinal Research Reviews, 1983. 3(2): p. 147–200. 6408323
23. el Igail A.B., et al., Dose-finding trial using Oltipraz to treat schoolchildren infected with Schistosoma mansoni in Gezira, Sudan. J Trop Med Hyg, 1985. 88(2): p. 101–4. 3897558
24. Benson A.B., 3rdOltipraz: a laboratory and clinical review. J Cell Biochem Suppl, 1993. 17F: p. 278–91. 8412206
25. Sander T., et al., DataWarrior: An Open-Source Program For Chemistry Aware Data Visualization And Analysis. Journal of Chemical Information and Modeling, 2015. 55(2): p. 460–473. doi: 10.1021/ci500588j25558886